AEZ Share Price

Open 4.52 Change Price %
High 4.70 1 Day 0.21 4.72
Low 4.52 1 Week 0.09 1.97
Close 4.66 1 Month 0.04 0.87
Volume 15706 1 Year -6.25 -57.29
52 Week High 10.77
52 Week Low 3.77
AEZ Important Levels
Resistance 2 4.83
Resistance 1 4.76
Pivot 4.63
Support 1 4.56
Support 2 4.49
TSE Canada Most Active Stocks
BIN 41.40 -1.62%
BIN 41.40 -1.62%
LSG 2.08 8.33%
LSG 2.08 8.33%
LSG 2.08 8.33%
TBE 0.03 0.00%
YRI 4.04 3.86%
SC 60.83 -0.44%
PRE 0.64 0.00%
PRE 0.64 0.00%
More..
TSE Canada Top Gainers Stocks
CUR 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
TVI 0.02 100.00%
TPL 0.02 100.00%
TPL 0.02 100.00%
ANX 0.06 20.00%
ANX 0.06 20.00%
MBA 0.57 11.76%
MBA 0.57 11.76%
More..
TSE Canada Top Losers Stocks
GBV 0.46 -24.59%
RN 0.10 -16.67%
RN 0.10 -16.67%
DNT 0.10 -16.67%
KOR 0.61 -11.59%
KOR 0.61 -11.59%
ONC 0.20 -9.09%
ONC 0.20 -9.09%
XTC 10.20 -6.93%
DEJ 0.14 -6.67%
More..

AEterna Zentaris, Inc. (TSE: AEZ)

AEZ Technical Analysis 2
As on 2nd Dec 2016 AEZ Share Price closed @ 4.66 and we RECOMMEND Buy for LONG-TERM with Stoploss of 4.64 & Strong Sell for SHORT-TERM with Stoploss of 4.86 we also expect STOCK to react on Following IMPORTANT LEVELS.
AEZ Target for December
1st Target up-side 5.2
2nd Target up-side 5.6
3rd Target up-side 6
1st Target down-side 4.06
2nd Target down-side 3.66
3rd Target down-side 3.26
AEZ Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.aezsinc.com
AEZ Address
AEZ
1405 du Parc-Technologique Boulevard
Quebec City, QC G1P 4P5
Canada
Phone: 418-652-8525
Fax: 418-948-9191
Interactive Technical Analysis Chart AEterna Zentaris, Inc. ( AEZ TSE Canada )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on AEterna Zentaris, Inc.
AEZ Business Profile
Aeterna Zentaris Inc., a specialty biopharmaceutical company, develops and commercializes novel treatments in oncology and endocrinology worldwide. The company’s product pipeline includes MACRILEN, a product candidate for which the company has filed a New Drug Application to the FDA as an oral product used for evaluating adult growth hormone deficiency; and is also investigated in Phase 2A clinical trials to treat cancer-induced cachexia. Its product pipeline also comprises Zoptarelin doxorubicin, which has completed Phase 2 clinical trials to treat ovarian and endometrial cancer, and breast cancer; and Phase 1/2 clinical trials to treat bladder and prostate cancers. In addition, the company’s product candidates in clinical and preclinical development consist of AEZS-120, a live recombinant oral tumor vaccine candidate; PI3K/Erk inhibitors, including AEZS-129 and AEZS-136 for oncology; and disorazol Z product candidates, such as AEZS-137 and AEZS-125 for oncology. Aeterna Zentaris Inc. was founded in 1990 and is headquartered in Quebec City, Canada.